David V. Sheehan: An Open-Label Study of Tiagabine in Panic Disorder

Name: David V. Sheehan: An Open-Label Study of Tiagabine in Panic Disorder
SKU: pb-40-3-sheehan
Price: 30.00 USD
Availability: InStock

$30.00

Want a discount? Become a member by purchasing Psychopharmacology Bulletin Subscription - Individual!

SKU: pb-40-3-sheehan Categories: Psychopharmacology Bulletin, VOL 40 No. 3 Articles Tags: aminobutyric-acid-gaba, anxiety, b-ashok-raj, david-v-sheehan, juris-janavs, kathy-harnett-sheehan, mba, md, panic-disorder, phd, selective-gaba-reuptake-inhibitor, tiagabine

Description

David V. Sheehan: An Open-Label Study of Tiagabine in Panic Disorder

Description

David V. Sheehan, MD Link

NEGATIVE AND FAILED CLINICAL TRIAL REPORTS

An Open-Label Study of Tiagabine in Panic Disorder

David V. Sheehan, MD, MBA, Kathy Harnett Sheehan, PhD, B. Ashok Raj, MD, and Juris Janavs, MD

Naomi M. Simon, MD: Bupropion Sustained Release for Panic Disorder

Establishing a ‘Gateway’ for Patients with Anxiety

Michael S. Clark, MD, PhD: The 5-HT1B Receptor: Behavioral Implications

David V. Sheehan: An Open-Label Study of Tiagabine in Panic Disorder

Description

David V. Sheehan, MD Link

NEGATIVE AND FAILED CLINICAL TRIAL REPORTS

An Open-Label Study of Tiagabine in Panic Disorder

David V. Sheehan, MD, MBA, Kathy Harnett Sheehan, PhD, B. Ashok Raj, MD, and Juris Janavs, MD

Related products

Naomi M. Simon, MD: Bupropion Sustained Release for Panic Disorder

Establishing a ‘Gateway’ for Patients with Anxiety

Social Anxiety Disorder: Doctor-Patient Guide

Michael S. Clark, MD, PhD: The 5-HT1B Receptor: Behavioral Implications